Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-03-23

AUTHORS

Xiaonan Hong, Yuqin Song, Huiqiang Huang, Bing Bai, Huilai Zhang, Xiaoyan Ke, Yuankai Shi, Jun Zhu, Guodong Lu, Stefan Liebscher, Chunxiao Cai

ABSTRACT

BACKGROUND: Peripheral T-cell lymphoma (PTCL) is associated with poor prognosis, particularly in patients with relapsed/refractory (R/R) disease. Pralatrexate, a folate analogue inhibitor, was the first drug approved to treat R/R PTCL. OBJECTIVE: As the distribution of PTCL subtypes differs between populations and few patients in the pivotal trial of pralatrexate were Asian, this study investigated the safety and efficacy of pralatrexate as monotherapy in Chinese patients with R/R PTCL. PATIENTS AND METHODS: In this single-arm, open-label, multicenter study, 71 patients with R/R PTCL (median [range] 2 [1-14] prior systemic treatments) were recruited from 15 centers in China and received pralatrexate IV 30 mg/m2/week for 6 weeks in 7-week cycles (with vitamin B12/folate). The primary endpoint was objective response rate (ORR) per central review (null hypothesis: ORR < 15%). RESULTS: The study's primary objective was met: ORR (95% CI) was 52% (40-64%) (p < 0.001) and responses were observed across pre-specified patient subgroups. Median (95% CI) duration of response was 8.7 (3.3-14.1) months and first response was observed in Cycle 1 for most (84%) patients. Median (95% CI) progression-free survival and overall survival was 4.8 (3.1-8.1) months and 18.0 (10.4-NA) months, respectively. The most common treatment-emergent adverse events were stomatitis (68% [Grade 3/4: 20%]), anemia (49% [Grade 3/4: 24%]) and alanine aminotransferase increase (41% [Grade 3/4: 4%]). CONCLUSIONS: These results demonstrate that pralatrexate may represent a promising treatment option for Chinese patients with R/R PTCL. The ORR of 52% compared favorably with prior studies of pralatrexate in other populations and there were no unanticipated side effects. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03349333. More... »

PAGES

1-10

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11523-019-00630-y

DOI

http://dx.doi.org/10.1007/s11523-019-00630-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112965789

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30904980


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Fudan University Shanghai Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.452404.3", 
          "name": [
            "Fudan University Shanghai Cancer Center, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hong", 
        "givenName": "Xiaonan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, No. 52 Fucheng Road, Haidian District, 100142, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Song", 
        "givenName": "Yuqin", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sun Yat-sen University Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.488530.2", 
          "name": [
            "Sun Yat-sen University Cancer Center, Guangzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Huang", 
        "givenName": "Huiqiang", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sun Yat-sen University Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.488530.2", 
          "name": [
            "Sun Yat-sen University Cancer Center, Guangzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bai", 
        "givenName": "Bing", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tianjin Medical University Cancer Institute and Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411918.4", 
          "name": [
            "Tianjin Medical University Cancer Institute and Hospital, Tianjin, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhang", 
        "givenName": "Huilai", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peking University Third Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411642.4", 
          "name": [
            "Peking University Third Hospital, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ke", 
        "givenName": "Xiaoyan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peking Union Medical College Hospital", 
          "id": "https://www.grid.ac/institutes/grid.413106.1", 
          "name": [
            "National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shi", 
        "givenName": "Yuankai", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, No. 52 Fucheng Road, Haidian District, 100142, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhu", 
        "givenName": "Jun", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Mundipharma (China) Pharmaceutical Co., Ltd, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lu", 
        "givenName": "Guodong", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mundipharma (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.476538.b", 
          "name": [
            "Mundipharma Research GmbH & Co. KG, Limburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Liebscher", 
        "givenName": "Stefan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Mundipharma (China) Pharmaceutical Co., Ltd, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cai", 
        "givenName": "Chunxiao", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/s13045-016-0243-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000335967", 
          "https://doi.org/10.1186/s13045-016-0243-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13045-016-0243-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000335967", 
          "https://doi.org/10.1186/s13045-016-0243-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1309/ajcp7yltqpusdq5c", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006957284"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.29.9024", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007463841"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2014.59.2782", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010415946"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdv237", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010781265"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2016-01-643569", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023194534"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.16.4558", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029891295"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-12-2251", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030092573"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2013-12-542142", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031182649"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1746-1596-6-77", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033104303", 
          "https://doi.org/10.1186/1746-1596-6-77"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-014-1520-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034106275", 
          "https://doi.org/10.1007/s12185-014-1520-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdv201", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038078668"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2014-04-573089", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047085552"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.44.7524", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050309061"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5402/2011/623924", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053736943"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2015.63.5540", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064204432"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.4.1244", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074549729"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13045-017-0439-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084251896", 
          "https://doi.org/10.1186/s13045-017-0439-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13045-017-0439-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084251896", 
          "https://doi.org/10.1186/s13045-017-0439-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3389/fphar.2017.00354", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085927485"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/cas.13340", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090995606"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.12688/f1000research.12573.1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099598065"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.12688/f1000research.12573.1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099598065"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-018-2404-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100752957", 
          "https://doi.org/10.1007/s12185-018-2404-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.6004/jnccn.2018.0007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101015899"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.6004/jnccn.2018.0007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101015899"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.6004/jnccn.2018.0007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101015899"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3324/haematol.2017.186577", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101833993"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3324/haematol.2017.186577", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101833993"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3324/haematol.2017.186577", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101833993"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3324/haematol.2017.186577", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101833993"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(18)32984-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1110345835"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(18)32984-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1110345835"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(18)32984-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1110345835"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(18)32984-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1110345835"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-03-23", 
    "datePublishedReg": "2019-03-23", 
    "description": "BACKGROUND: Peripheral T-cell lymphoma (PTCL) is associated with poor prognosis, particularly in patients with relapsed/refractory (R/R) disease. Pralatrexate, a folate analogue inhibitor, was the first drug approved to treat R/R PTCL.\nOBJECTIVE: As the distribution of PTCL subtypes differs between populations and few patients in the pivotal trial of pralatrexate were Asian, this study investigated the safety and efficacy of pralatrexate as monotherapy in Chinese patients with R/R PTCL.\nPATIENTS AND METHODS: In this single-arm, open-label, multicenter study, 71 patients with R/R PTCL (median [range] 2 [1-14] prior systemic treatments) were recruited from 15 centers in China and received pralatrexate IV 30\u00a0mg/m2/week for 6\u00a0weeks in 7-week cycles (with vitamin B12/folate). The primary endpoint was objective response rate (ORR) per central review (null hypothesis: ORR <\u200915%).\nRESULTS: The study's primary objective was met: ORR (95% CI) was 52% (40-64%) (p\u2009<\u20090.001) and responses were observed across pre-specified patient subgroups. Median (95% CI) duration of response was 8.7 (3.3-14.1) months and first response was observed in Cycle 1 for most (84%) patients. Median (95% CI) progression-free survival and overall survival was 4.8 (3.1-8.1) months and 18.0 (10.4-NA) months, respectively. The most common treatment-emergent adverse events were stomatitis (68% [Grade 3/4: 20%]), anemia (49% [Grade 3/4: 24%]) and alanine aminotransferase increase (41% [Grade 3/4: 4%]).\nCONCLUSIONS: These results demonstrate that pralatrexate may represent a promising treatment option for Chinese patients with R/R PTCL. The ORR of 52% compared favorably with prior studies of pralatrexate in other populations and there were no unanticipated side effects.\nTRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03349333.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s11523-019-00630-y", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1036678", 
        "issn": [
          "1776-2596", 
          "1776-260X"
        ], 
        "name": "Targeted Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "14"
      }
    ], 
    "name": "Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study", 
    "pagination": "1-10", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11523-019-00630-y"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "ac55fbec874b125b18b8944bcd98b0a80f653cf069b083ba2b607a771d4f96d4"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112965789"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101270595"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30904980"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11523-019-00630-y", 
      "https://app.dimensions.ai/details/publication/pub.1112965789"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-15T08:48", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000374_0000000374/records_119717_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs11523-019-00630-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11523-019-00630-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11523-019-00630-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11523-019-00630-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11523-019-00630-y'


 

This table displays all metadata directly associated to this object as RDF triples.

231 TRIPLES      21 PREDICATES      53 URIs      20 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11523-019-00630-y schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Nc8b57b3bab4b4bb7928b1cc41a4f8532
4 schema:citation sg:pub.10.1007/s12185-014-1520-3
5 sg:pub.10.1007/s12185-018-2404-8
6 sg:pub.10.1186/1746-1596-6-77
7 sg:pub.10.1186/s13045-016-0243-8
8 sg:pub.10.1186/s13045-017-0439-6
9 https://doi.org/10.1016/s0140-6736(18)32984-2
10 https://doi.org/10.1093/annonc/mdv201
11 https://doi.org/10.1093/annonc/mdv237
12 https://doi.org/10.1111/cas.13340
13 https://doi.org/10.1158/1078-0432.ccr-12-2251
14 https://doi.org/10.1182/blood-2013-12-542142
15 https://doi.org/10.1182/blood-2014-04-573089
16 https://doi.org/10.1182/blood-2016-01-643569
17 https://doi.org/10.1200/jco.1999.17.4.1244
18 https://doi.org/10.1200/jco.2008.16.4558
19 https://doi.org/10.1200/jco.2010.29.9024
20 https://doi.org/10.1200/jco.2012.44.7524
21 https://doi.org/10.1200/jco.2014.59.2782
22 https://doi.org/10.1200/jco.2015.63.5540
23 https://doi.org/10.12688/f1000research.12573.1
24 https://doi.org/10.1309/ajcp7yltqpusdq5c
25 https://doi.org/10.3324/haematol.2017.186577
26 https://doi.org/10.3389/fphar.2017.00354
27 https://doi.org/10.5402/2011/623924
28 https://doi.org/10.6004/jnccn.2018.0007
29 schema:datePublished 2019-03-23
30 schema:datePublishedReg 2019-03-23
31 schema:description BACKGROUND: Peripheral T-cell lymphoma (PTCL) is associated with poor prognosis, particularly in patients with relapsed/refractory (R/R) disease. Pralatrexate, a folate analogue inhibitor, was the first drug approved to treat R/R PTCL. OBJECTIVE: As the distribution of PTCL subtypes differs between populations and few patients in the pivotal trial of pralatrexate were Asian, this study investigated the safety and efficacy of pralatrexate as monotherapy in Chinese patients with R/R PTCL. PATIENTS AND METHODS: In this single-arm, open-label, multicenter study, 71 patients with R/R PTCL (median [range] 2 [1-14] prior systemic treatments) were recruited from 15 centers in China and received pralatrexate IV 30 mg/m2/week for 6 weeks in 7-week cycles (with vitamin B12/folate). The primary endpoint was objective response rate (ORR) per central review (null hypothesis: ORR < 15%). RESULTS: The study's primary objective was met: ORR (95% CI) was 52% (40-64%) (p < 0.001) and responses were observed across pre-specified patient subgroups. Median (95% CI) duration of response was 8.7 (3.3-14.1) months and first response was observed in Cycle 1 for most (84%) patients. Median (95% CI) progression-free survival and overall survival was 4.8 (3.1-8.1) months and 18.0 (10.4-NA) months, respectively. The most common treatment-emergent adverse events were stomatitis (68% [Grade 3/4: 20%]), anemia (49% [Grade 3/4: 24%]) and alanine aminotransferase increase (41% [Grade 3/4: 4%]). CONCLUSIONS: These results demonstrate that pralatrexate may represent a promising treatment option for Chinese patients with R/R PTCL. The ORR of 52% compared favorably with prior studies of pralatrexate in other populations and there were no unanticipated side effects. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03349333.
32 schema:genre research_article
33 schema:inLanguage en
34 schema:isAccessibleForFree false
35 schema:isPartOf N24ebd08e44224f6dbc5bd72c16e1e578
36 Ndea987feeac04ef0a2b1c2e402cc9ab4
37 sg:journal.1036678
38 schema:name Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study
39 schema:pagination 1-10
40 schema:productId N1b2919f2955045b987eb80b58dd901a3
41 N3cb0f96e75b943aea53526b14af2fb9c
42 N54b108ffddf942d991d220c23d889989
43 N90eedd9e766b47ba8b43e4fbab78062d
44 Nd5f8ae9b6ab34e8ea31786d7a794d9a8
45 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112965789
46 https://doi.org/10.1007/s11523-019-00630-y
47 schema:sdDatePublished 2019-04-15T08:48
48 schema:sdLicense https://scigraph.springernature.com/explorer/license/
49 schema:sdPublisher N9a89d21ee88e41b080f333d6a205da16
50 schema:url https://link.springer.com/10.1007%2Fs11523-019-00630-y
51 sgo:license sg:explorer/license/
52 sgo:sdDataset articles
53 rdf:type schema:ScholarlyArticle
54 N04e89588498c47a6a14296a0117029a5 schema:name Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, No. 52 Fucheng Road, Haidian District, 100142, Beijing, China
55 rdf:type schema:Organization
56 N15ac0618129a407e8272f999a47e3be4 schema:affiliation Nacde9944daa74ba3a945cfc47333dc84
57 schema:familyName Cai
58 schema:givenName Chunxiao
59 rdf:type schema:Person
60 N1b2919f2955045b987eb80b58dd901a3 schema:name readcube_id
61 schema:value ac55fbec874b125b18b8944bcd98b0a80f653cf069b083ba2b607a771d4f96d4
62 rdf:type schema:PropertyValue
63 N24ebd08e44224f6dbc5bd72c16e1e578 schema:issueNumber 2
64 rdf:type schema:PublicationIssue
65 N25aa122d739a4332b6e35fc6db71e54a rdf:first Nd8ebca70c65542cf8b5d4a486c9638b8
66 rdf:rest Nde3fb7387305435dbc316ce6bd04372b
67 N25c47088d61643509e610c9678fa6099 schema:affiliation Nb6ed1e9ee81a4bff90e159fdd3bc4353
68 schema:familyName Song
69 schema:givenName Yuqin
70 rdf:type schema:Person
71 N3a812440b0e847328815772453f07ff9 schema:name Mundipharma (China) Pharmaceutical Co., Ltd, Beijing, China
72 rdf:type schema:Organization
73 N3cb0f96e75b943aea53526b14af2fb9c schema:name nlm_unique_id
74 schema:value 101270595
75 rdf:type schema:PropertyValue
76 N400a2b3556654026be784ffb1d5df792 schema:affiliation https://www.grid.ac/institutes/grid.452404.3
77 schema:familyName Hong
78 schema:givenName Xiaonan
79 rdf:type schema:Person
80 N439d5133eda84f40bcf301bf7c0719ef rdf:first Nce31b8416a0d41509d9c35bfd11c2876
81 rdf:rest Nafe7b26bb05745b08031c8cf7973779b
82 N4ac8f7963b6f40d58757ae5fe19fb1ad rdf:first Nd188121c5c884f94803bf420ede1cd0f
83 rdf:rest Nd0fe9365fde540929e543414f4089720
84 N54b108ffddf942d991d220c23d889989 schema:name doi
85 schema:value 10.1007/s11523-019-00630-y
86 rdf:type schema:PropertyValue
87 N61924634d23d4cabb61d51cd88e202cb schema:affiliation https://www.grid.ac/institutes/grid.411642.4
88 schema:familyName Ke
89 schema:givenName Xiaoyan
90 rdf:type schema:Person
91 N7333e2df85244dc19a1a0ca7f3184249 schema:affiliation https://www.grid.ac/institutes/grid.411918.4
92 schema:familyName Zhang
93 schema:givenName Huilai
94 rdf:type schema:Person
95 N7c757e6e3b0d4f389e01e4f6797d6db5 rdf:first N7333e2df85244dc19a1a0ca7f3184249
96 rdf:rest Nc57d45291ed743739efa56d0e57d9f02
97 N7f3c98cce93f494f82d35dcb39405f83 schema:affiliation https://www.grid.ac/institutes/grid.413106.1
98 schema:familyName Shi
99 schema:givenName Yuankai
100 rdf:type schema:Person
101 N8012445ea15f45ad81693759e9b21920 rdf:first N7f3c98cce93f494f82d35dcb39405f83
102 rdf:rest N25aa122d739a4332b6e35fc6db71e54a
103 N90eedd9e766b47ba8b43e4fbab78062d schema:name dimensions_id
104 schema:value pub.1112965789
105 rdf:type schema:PropertyValue
106 N92df137b3041425b86fd7f1fcef0f92f schema:affiliation N3a812440b0e847328815772453f07ff9
107 schema:familyName Lu
108 schema:givenName Guodong
109 rdf:type schema:Person
110 N9a89d21ee88e41b080f333d6a205da16 schema:name Springer Nature - SN SciGraph project
111 rdf:type schema:Organization
112 Naaa5f8d3df834a54970c9d5948b0cf5b rdf:first N25c47088d61643509e610c9678fa6099
113 rdf:rest N4ac8f7963b6f40d58757ae5fe19fb1ad
114 Nacde9944daa74ba3a945cfc47333dc84 schema:name Mundipharma (China) Pharmaceutical Co., Ltd, Beijing, China
115 rdf:type schema:Organization
116 Nafe7b26bb05745b08031c8cf7973779b rdf:first N15ac0618129a407e8272f999a47e3be4
117 rdf:rest rdf:nil
118 Nb6ed1e9ee81a4bff90e159fdd3bc4353 schema:name Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, No. 52 Fucheng Road, Haidian District, 100142, Beijing, China
119 rdf:type schema:Organization
120 Nc57d45291ed743739efa56d0e57d9f02 rdf:first N61924634d23d4cabb61d51cd88e202cb
121 rdf:rest N8012445ea15f45ad81693759e9b21920
122 Nc6a8b35f64cb4ec0ac05f62c80af14ed schema:affiliation https://www.grid.ac/institutes/grid.488530.2
123 schema:familyName Bai
124 schema:givenName Bing
125 rdf:type schema:Person
126 Nc8b57b3bab4b4bb7928b1cc41a4f8532 rdf:first N400a2b3556654026be784ffb1d5df792
127 rdf:rest Naaa5f8d3df834a54970c9d5948b0cf5b
128 Nce31b8416a0d41509d9c35bfd11c2876 schema:affiliation https://www.grid.ac/institutes/grid.476538.b
129 schema:familyName Liebscher
130 schema:givenName Stefan
131 rdf:type schema:Person
132 Nd0fe9365fde540929e543414f4089720 rdf:first Nc6a8b35f64cb4ec0ac05f62c80af14ed
133 rdf:rest N7c757e6e3b0d4f389e01e4f6797d6db5
134 Nd188121c5c884f94803bf420ede1cd0f schema:affiliation https://www.grid.ac/institutes/grid.488530.2
135 schema:familyName Huang
136 schema:givenName Huiqiang
137 rdf:type schema:Person
138 Nd5f8ae9b6ab34e8ea31786d7a794d9a8 schema:name pubmed_id
139 schema:value 30904980
140 rdf:type schema:PropertyValue
141 Nd8ebca70c65542cf8b5d4a486c9638b8 schema:affiliation N04e89588498c47a6a14296a0117029a5
142 schema:familyName Zhu
143 schema:givenName Jun
144 rdf:type schema:Person
145 Nde3fb7387305435dbc316ce6bd04372b rdf:first N92df137b3041425b86fd7f1fcef0f92f
146 rdf:rest N439d5133eda84f40bcf301bf7c0719ef
147 Ndea987feeac04ef0a2b1c2e402cc9ab4 schema:volumeNumber 14
148 rdf:type schema:PublicationVolume
149 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
150 schema:name Medical and Health Sciences
151 rdf:type schema:DefinedTerm
152 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
153 schema:name Clinical Sciences
154 rdf:type schema:DefinedTerm
155 sg:journal.1036678 schema:issn 1776-2596
156 1776-260X
157 schema:name Targeted Oncology
158 rdf:type schema:Periodical
159 sg:pub.10.1007/s12185-014-1520-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034106275
160 https://doi.org/10.1007/s12185-014-1520-3
161 rdf:type schema:CreativeWork
162 sg:pub.10.1007/s12185-018-2404-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100752957
163 https://doi.org/10.1007/s12185-018-2404-8
164 rdf:type schema:CreativeWork
165 sg:pub.10.1186/1746-1596-6-77 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033104303
166 https://doi.org/10.1186/1746-1596-6-77
167 rdf:type schema:CreativeWork
168 sg:pub.10.1186/s13045-016-0243-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000335967
169 https://doi.org/10.1186/s13045-016-0243-8
170 rdf:type schema:CreativeWork
171 sg:pub.10.1186/s13045-017-0439-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084251896
172 https://doi.org/10.1186/s13045-017-0439-6
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1016/s0140-6736(18)32984-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1110345835
175 rdf:type schema:CreativeWork
176 https://doi.org/10.1093/annonc/mdv201 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038078668
177 rdf:type schema:CreativeWork
178 https://doi.org/10.1093/annonc/mdv237 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010781265
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1111/cas.13340 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090995606
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1158/1078-0432.ccr-12-2251 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030092573
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1182/blood-2013-12-542142 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031182649
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1182/blood-2014-04-573089 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047085552
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1182/blood-2016-01-643569 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023194534
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1200/jco.1999.17.4.1244 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074549729
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1200/jco.2008.16.4558 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029891295
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1200/jco.2010.29.9024 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007463841
195 rdf:type schema:CreativeWork
196 https://doi.org/10.1200/jco.2012.44.7524 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050309061
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1200/jco.2014.59.2782 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010415946
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1200/jco.2015.63.5540 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064204432
201 rdf:type schema:CreativeWork
202 https://doi.org/10.12688/f1000research.12573.1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099598065
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1309/ajcp7yltqpusdq5c schema:sameAs https://app.dimensions.ai/details/publication/pub.1006957284
205 rdf:type schema:CreativeWork
206 https://doi.org/10.3324/haematol.2017.186577 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101833993
207 rdf:type schema:CreativeWork
208 https://doi.org/10.3389/fphar.2017.00354 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085927485
209 rdf:type schema:CreativeWork
210 https://doi.org/10.5402/2011/623924 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053736943
211 rdf:type schema:CreativeWork
212 https://doi.org/10.6004/jnccn.2018.0007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101015899
213 rdf:type schema:CreativeWork
214 https://www.grid.ac/institutes/grid.411642.4 schema:alternateName Peking University Third Hospital
215 schema:name Peking University Third Hospital, Beijing, China
216 rdf:type schema:Organization
217 https://www.grid.ac/institutes/grid.411918.4 schema:alternateName Tianjin Medical University Cancer Institute and Hospital
218 schema:name Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
219 rdf:type schema:Organization
220 https://www.grid.ac/institutes/grid.413106.1 schema:alternateName Peking Union Medical College Hospital
221 schema:name National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
222 rdf:type schema:Organization
223 https://www.grid.ac/institutes/grid.452404.3 schema:alternateName Fudan University Shanghai Cancer Center
224 schema:name Fudan University Shanghai Cancer Center, Shanghai, China
225 rdf:type schema:Organization
226 https://www.grid.ac/institutes/grid.476538.b schema:alternateName Mundipharma (Germany)
227 schema:name Mundipharma Research GmbH & Co. KG, Limburg, Germany
228 rdf:type schema:Organization
229 https://www.grid.ac/institutes/grid.488530.2 schema:alternateName Sun Yat-sen University Cancer Center
230 schema:name Sun Yat-sen University Cancer Center, Guangzhou, China
231 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...